J 2022

Combined efficacy of Cinnamomum zeylanicum and doxorubicin against leukemia through regulation of TRAIL and NF-kappa B pathways in rat model.

BUKHARI, Sidra, Muhammad Hamid SIDDIQUE, Anum NAEEM, InamUllah KHAN, Zain ALI et. al.

Basic information

Original name

Combined efficacy of Cinnamomum zeylanicum and doxorubicin against leukemia through regulation of TRAIL and NF-kappa B pathways in rat model.

Authors

BUKHARI, Sidra, Muhammad Hamid SIDDIQUE, Anum NAEEM, InamUllah KHAN, Zain ALI, Asiya ESSA, Falak FAZAL, Riffat Aysha ANIS, Lukáš MORÁŇ (203 Czech Republic, belonging to the institution), Aneesa SULTAN, Iram MURTAZA, Petr VAŇHARA (203 Czech Republic, belonging to the institution) and Mariam ANEES (guarantor)

Edition

Molecular Biology Reports, DORDRECHT, SPRINGER, 2022, 0301-4851

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10608 Biochemistry and molecular biology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.800

RIV identification code

RIV/00216224:14110/22:00125992

Organization unit

Faculty of Medicine

UT WoS

000796808200007

Keywords (in Czech)

Cinnamomum zeylanicum; Doxorubicin; Akutní myeloidní leukemie; TRAIL; NF-kappa B; Rat model

Keywords in English

Cinnamomum zeylanicum; Doxorubicin; Acute myeloid leukemia; TRAIL; NF-kappa B; Rat model

Tags

Tags

International impact, Reviewed
Změněno: 3/4/2023 09:07, Mgr. Tereza Miškechová

Abstract

V originále

Background: Recent discoveries in cancer therapeutics have proven combination therapies more effective than individual drugs. This study describes the efficacy of the combination of Cinnamomum zeylanicum and doxorubicin against benzene-induced leukemia. Methods and results: Brine shrimp assay was used to assess the cytotoxicity of C. zeylanicum, doxorubicin and their combination. After AML induction in Sprague Dawley rats, the same drugs were given to rat groups. Changes in organ weight, haematological profile, and hepatic enzymes were determined. Real-time PCR was used to elucidate the effect on the expression of STMN1, GAPDH, P53 and various TRAIL and NF-kappaB components. C. zeylanicum reduced the cytotoxicity of doxorubicin. The combination treatment showed better anti-leukemic results than any of the individual drugs as evident from STMN1 expression (p < 0.001). It was particularly effective in reducing total white blood cell counts and recovering lymphocytes, monocytes and eosinophils along with hepatic enzymes ALT and AST (p < 0.001). All doses recovered relative organ weights and improved blood parameters. The combination therapy was particularly effective in inducing apoptosis, inhibition of proliferation marker GAPDH (p < 0.001) and NF-kappaB pathway components Rel-A (p < 0.001) and Rel-B (p < 0.01). Expressions of TRAIL components c-FLIP (p < 0.001), TRAIL ligand (p < 0.001) and caspase 8 (p < 0.01) were also altered. Conclusion: Cinnamomum zeylanicum in combination with doxorubicin helps to counter benzene-induced cellular and hepatic toxicity and improves haematological profile. The anti-leukemic effects are potentially due to inhibition of GAPDH and NF-kappa B pathway, and through regulation of TRAIL pathway. Our data suggests the use of C. zeylanicum with doxorubicin to improve anti-leukemic therapeutic regimes.